Immunocore
A leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases.
Launch date
Employees
Market cap
€1.5b
Enterprise valuation
€1.2b (Public information from Sep 2024)
Share price
$34.44 IMCR
Company register number 06456207
Milton England (HQ)
Financials
Estimates*
| GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 30.1m | 26.5m | 144m | 249m | 240m | 268m | 288m |
| % growth | 17 % | (12 %) | 442 % | 74 % | (4 %) | 12 % | 7 % |
| EBITDA | (75.4m) | (135m) | (36.5m) | (38.5m) | (72.4m) | (110m) | (111m) |
| % EBITDA margin | (251 %) | (509 %) | (25 %) | (15 %) | (30 %) | (41 %) | (39 %) |
| Profit | (74.1m) | (132m) | (41.2m) | (55.3m) | (70.1m) | (83.1m) | (103m) |
| % profit margin | (246 %) | (496 %) | (29 %) | (22 %) | (29 %) | (31 %) | (36 %) |
| EV / revenue | - | 35.2x | 14.0x | 9.4x | 4.6x | 4.4x | 4.6x |
| EV / EBITDA | - | -6.9x | -55.0x | -60.8x | -15.2x | -10.9x | -11.9x |
| R&D budget | 74.8m | 73.2m | 89.2m | 164m | - | - | - |
| R&D % of revenue | 248 % | 276 % | 62 % | 66 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Corporate spinout | ||
N/A | Grant | ||
£2.4m | Grant | ||
$320m Valuation: $950m -98.4x EV/LTM EBITDA | Series A | ||
* | $40.0m | Series B | |
$130m Valuation: $620m 18.3x EV/LTM Revenues -4.4x EV/LTM EBITDA | Series B | ||
$75.0m | Series C | ||
| N/A | $43.2m Valuation: $1.2b 29.7x EV/LTM Revenues -11.8x EV/LTM EBITDA | IPO | |
* | $140m | Private Placement VC | |
* | N/A | $300m | Post IPO Convertible |
| Total Funding | €644m | ||
Recent News about Immunocore
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.